Dr. Robert A. Hirsch
Claim this profileMemorial Regional Hospital/Joe DiMaggio Children's Hospital
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
3 reported clinical trials
9 drugs studied
Area of expertise
1Lung Cancer
Stage I
Stage II
Stage IV
2Non-Small Cell Lung Cancer
Stage I
Stage II
Stage IV
Affiliated Hospitals
Clinical Trials Robert A. Hirsch is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
More about Robert A. Hirsch
Clinical Trial Related5 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Robert A. Hirsch has experience with
- Crizotinib
- Screening Platform
- Pembrolizumab
- Ramucirumab
- Docetaxel
- Pemetrexed
Breakdown of trials Robert A. Hirsch has run
Lung Cancer
Non-Small Cell Lung Cancer
ALK Gene Rearrangement
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robert A. Hirsch specialize in?
Robert A. Hirsch focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage I patients, or patients who are Stage II.
Is Robert A. Hirsch currently recruiting for clinical trials?
Yes, Robert A. Hirsch is currently recruiting for 2 clinical trials in Hollywood Florida. If you're interested in participating, you should apply.
Are there any treatments that Robert A. Hirsch has studied deeply?
Yes, Robert A. Hirsch has studied treatments such as Crizotinib, Screening Platform, Pembrolizumab.
What is the best way to schedule an appointment with Robert A. Hirsch?
Apply for one of the trials that Robert A. Hirsch is conducting.
What is the office address of Robert A. Hirsch?
The office of Robert A. Hirsch is located at: Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida 33021 United States. This is the address for their practice at the Memorial Regional Hospital/Joe DiMaggio Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.